Loading…
TTK Healthcare (TTKHLTCARE)₹927.55−0.45%Diversified
In the Jun 2026 quarter (standalone), TTK Healthcare reported sales of ₹257 Cr, up 14.2% from Jun 2025, and net profit of ₹21.02 Cr, up 61.6% year on year. For the year to Mar 2026, sales were ₹854 Cr and net profit ₹66.07 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 185 | 183 | 180 | 207 | 197 | 204 | 189 | 225 | 203 | 208 | 217 | 257 |
| Expenses | 176 | 179 | 169 | 201 | 190 | 197 | 178 | 224 | 198 | 202 | 207 | 243 |
| Operating Profit | 10.02 | 5.01 | 12.04 | 7.02 | 8.02 | 8.02 | 12.04 | 3.01 | 5.01 | 7.02 | 11.04 | 15.04 |
| OPM % | 5.0% | 2.9% | 7.0% | 3.3% | 4.2% | 3.8% | 6.0% | 1.2% | 2.6% | 3.4% | 5.0% | 6.0% |
| Other Income | 15.99 | 15.99 | 15.99 | 36.97 | 17.98 | 17.98 | 12.99 | 18.01 | 18.98 | 9.99 | 20.99 | 17.01 |
| Interest | 1.01 | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
| Depreciation | 3.01 | 3.01 | 3.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 |
| Profit before tax | 21.95 | 17.95 | 23.92 | 40.87 | 22.93 | 22.95 | 21.94 | 17.96 | 20.96 | 13.97 | 29.93 | 28.92 |
| Tax % | 26.0% | 27.0% | 25.0% | 23.0% | 26.1% | 26.0% | 26.1% | 26.0% | 4.0% | 25.0% | 26.1% | 26.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 15.01 | 0.00 | 0.00 | −4.01 | 0.00 | 0.00 | −5.01 | 3.01 | 0.00 |
| Net Profit | 16.01 | 13.01 | 18.01 | 32.01 | 17.02 | 17.01 | 16.01 | 13.01 | 20.03 | 11.01 | 22.02 | 21.02 |
| EPS (Rs) | 11.32 | 9.11 | 12.90 | 22.29 | 12.14 | 11.81 | 11.41 | 9.18 | 14.41 | 7.43 | 15.37 | 15.03 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 517 | 526 | 576 | 626 | 644 | 474 | 597 | 722 | 751 | 798 | 854 | 886 |
| Expenses | 478 | 489 | 535 | 578 | 617 | 457 | 577 | 694 | 715 | 767 | 831 | 850 |
| Operating Profit | 40.13 | 38.13 | 43.15 | 50.14 | 28.09 | 19.06 | 22.08 | 31.11 | 37.13 | 35.11 | 26.10 | 38.11 |
| OPM % | 8.0% | 7.0% | 7.0% | 8.0% | 4.4% | 4.1% | 3.6% | 4.3% | 5.0% | 4.3% | 3.0% | 4.3% |
| Other Income | 6.01 | 5.99 | 8.01 | 7.99 | 8.99 | 27.99 | 41.99 | 643 | 62.98 | 84.98 | 67.97 | 66.97 |
| Interest | 3.01 | 3.01 | 5.02 | 3.01 | 3.01 | 2.01 | 3.01 | 5.02 | 3.01 | 3.01 | 3.01 | 4.04 |
| Depreciation | 7.01 | 12.01 | 15.02 | 15.03 | 14.02 | 13.01 | 13.01 | 13.01 | 13.01 | 8.01 | 9.01 | 8.04 |
| Profit before tax | 35.89 | 28.91 | 29.93 | 38.87 | 18.96 | 31.93 | 47.90 | 656 | 83.71 | 108 | 82.80 | 93.78 |
| Tax % | 36.0% | 36.0% | 40.0% | 38.0% | 37.0% | −44.0% | 13.0% | 3.0% | 25.0% | 25.1% | 20.1% | — |
| Exceptional items | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 | 6.01 | 2.01 | 0.00 | 0.00 | 10.01 | −3.01 | −2.00 |
| Net Profit | 23.03 | 19.01 | 18.02 | 24.02 | 12.01 | 46.03 | 42.04 | 640 | 63.02 | 82.01 | 66.07 | 74.08 |
| EPS (Rs) | 29.15 | 24.09 | 12.84 | 17.20 | 8.70 | 32.80 | 29.39 | 452.01 | 44.37 | 57.68 | 46.40 | 52.24 |
| Dividend payout % | 17.0% | 21.0% | 39.0% | 29.0% | 34.0% | 18.0% | 34.0% | 2.0% | 22.0% | 17.0% | 22.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.99 | 7.99 | 7.99 | 14.01 | 13.99 | 13.99 | 13.99 | 13.99 | 13.98 | 13.99 | 14.01 | 13.98 |
| Reserves | 110 | 129 | 151 | 220 | 238 | 236 | 282 | 317 | 942 | 990 | 1,055 | 1,105 |
| Borrowings | 42.13 | 38.12 | 23.05 | 47.11 | 29.07 | 30.07 | 19.06 | 22.07 | 27.05 | 23.05 | 24.05 | 24.03 |
| Other Liabilities | 115 | 128 | 104 | 127 | 136 | 152 | 180 | 207 | 188 | 183 | 191 | 189 |
| Total Liabilities | 275 | 303 | 286 | 408 | 417 | 432 | 495 | 560 | 1,172 | 1,210 | 1,284 | 1,332 |
| Fixed Assets | 51.92 | 106 | 98.94 | 110 | 97.89 | 88.91 | 84.92 | 79.84 | 70.87 | 74.84 | 80.91 | 72.92 |
| CWIP | 45.87 | 0.99 | 0.00 | 0.99 | 1.99 | 8.97 | 0.00 | 0.00 | 2.99 | 0.99 | 0.00 | 0.99 |
| Investments | 0.00 | 10.02 | 9.02 | 9.01 | 13.02 | 9.01 | 13.02 | 15.04 | 13.02 | 13.04 | 11.03 | 9.02 |
| Other Assets | 178 | 186 | 178 | 289 | 305 | 326 | 396 | 464 | 1,085 | 1,122 | 1,192 | 1,249 |
| Inventories | 36.89 | 40.88 | 43.82 | 52.81 | 54.85 | 71.70 | 69.78 | 78.75 | 84.72 | 96.71 | 109 | 109 |
| Trade receivables | 43.89 | 46.88 | 33.93 | 54.85 | 79.83 | 76.82 | 59.84 | 53.88 | 91.83 | 85.76 | 90.72 | 111 |
| Cash & equivalents | 76.70 | 76.76 | 81.72 | 135 | 126 | 132 | 227 | 273 | 845 | 772 | 784 | 631 |
| Total Assets | 275 | 303 | 286 | 408 | 417 | 432 | 495 | 560 | 1,172 | 1,210 | 1,284 | 1,332 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 38.94 | 36.90 | 17.97 | 24.94 | 16.96 | 19.96 | 95.81 | 44.89 | −24.97 | −4.99 | −3.99 | −20.95 |
| Cash from investing activity | −48.98 | −26.98 | 4.99 | −21.97 | 9.99 | −13.01 | −76.96 | −29.96 | 32.01 | 27.99 | 20.01 | 51.99 |
| Cash from financing activity | 3.01 | −11.02 | −23.02 | −7.01 | −31.04 | −10.01 | −17.03 | −10.01 | −12.01 | −22.02 | −18.03 | −18.02 |
| Net cash flow | −7.02 | 0.00 | 0.00 | −4.01 | −4.02 | −4.02 | 2.01 | 5.02 | −6.02 | 2.01 | −2.01 | 13.05 |
| Capex | 48.83 | 16.93 | 4.98 | 3.98 | 3.98 | 11.95 | 1.99 | 5.98 | 11.96 | 9.97 | 12.96 | 5.98 |
| Free cash flow | −9.99 | 20.96 | 11.97 | 20.96 | 12.98 | 7.99 | 94.82 | 41.96 | −35.97 | −14.97 | 5.99 | −24.96 |
| CFO / OP % | 176.1% | 122.0% | 67.0% | 84.1% | 62.0% | 108.0% | 391.1% | 248.1% | −28.0% | 54.0% | 68.0% | −31.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 34 | 33 | 24 | 35 | 47 | 43 | 46 | 33 | 46 | 42 | 41 | 47 |
| Inventory days | 62 | 66 | 65 | 80 | 77 | 101 | 123 | 102 | 89 | 105 | 107 | 98 |
| Days payable | 50 | 53 | 100 | 130 | 101 | 121 | 170 | 134 | 116 | 110 | 106 | 83 |
| Cash conversion cycle | 45 | 45 | −12 | −17 | 21 | 22 | −3 | 0 | 18 | 35 | 42 | 62 |
| Working capital days | −30 | −37 | −23 | −29 | −5 | −2 | −31 | −27 | 5 | 50 | 49 | 162 |
| ROCE % | 20.1% | 23.1% | 18.1% | 15.1% | 15.1% | 8.1% | 6.0% | 8.1% | 10.1% | 9.0% | 9.1% | 8.0% |
For the Jun 2026 quarter, TTK Healthcare reported sales of ₹257 Cr, up 14.2% year on year and net profit of ₹21.02 Cr, up 61.6% year on year. The operating margin was 6.0%.
TTK Healthcare's sales for the year to Mar 2026 were ₹854 Cr; over the last twelve months they were ₹886 Cr.
Net profit for the year to Mar 2026 was ₹66.07 Cr, and ₹74.08 Cr over the last twelve months. Earnings per share over the same trailing period were ₹52.24.
TTK Healthcare reported borrowings of ₹24.03 Cr at Mar 2026, against cash and equivalents of ₹631 Cr.
Cash from operations was −₹20.95 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹24.96 Cr.